🚨Amazing presentation by Dr. Mariana Chavez MacGregor at #ASCO25 #IMGoncCoP meeting!! Sharing amazing insights at our 3rd annual meeting!! 📍Room S103 ASCO OncoAlert ASCO TECAG Hem-Onc Fellows Network

Really honored to received this ASCO YIA. Grateful to the Conquer Cancer, the ASCO Foundation to support our work and to my outstanding mentors Dr. Ron DePinho Michael overman for their continuous support!

Our Duke breast onc family at ASCO ❤️ ASCO Duke Cancer Heather Moore Carey Anders Marija Sullivan, MD

Feeling incredibly grateful to be joining this amazing group of breast oncology colleagues at Duke this fall! 💙#ASCO25

Strong work form MD Anderson Cancer Center co-fellow Afsaneh Amouzegar, MD understanding KIT mutations and risk of CNS metastases in mucosal melanoma. #ASCO2025 #endcancer

Insightful work from my MD Anderson Cancer Center co-fellow and friend Afsaneh Amouzegar, MD on the association between KIT mutations and CNS metastases in mucosal melanoma. #ASCO25

Huge congrats to my friend and MD Anderson Cancer Center cofellow Ryan Denu, MD, PhD on his oral presentation at #ASCO25, identifying two new leiomyosarcoma subtypes with distinct biology and immune profiles using spatial transcriptomics. Incredible work!

Spatial transcriptomics revealed two new subtypes of leiomyosarcoma that are potential prognostic biomarkers for this rare and aggressive type of soft tissue sarcoma. Our fellow, Dr. Ryan Denu, MD, PhD presented results at an #ASCO25 session moderated by our Dr. Elise Nassif Haddad. Read more:

Great point by Angie DeMichele: should PFS2 in SERENA-6 include the post-cami treatment? That creates an imbalance, since it compares patients that received a sequence of 3 treatments to patients that only received 2. #ASCO25

1000% agree - Angie DeMichele, MD, MSCE, FASCO broke down each point so well and gave great insights on how we should think about this data and its potential limitations in clinical practice right now ASCO #bcsm

The breast onc sisters meet the Oncology Brothers at #MiamiNights #ASCO25

DB-09 📣by Sara Tolaney TDxd + P vs THP Great review by Dr. Isaacs of results we need QOL data especially for pts on maintenance HP vs TDxd, we know clinically that there is MUCH more tox w/ TDxd & many pts experience great QOL on HP maintenance therapy ASCO #bcsm

So proud of co-fellow Marija Sullivan, MD on a great presentation on real world implementation of Oncotype results. MD Anderson Cancer Center #ASCO25 #endcancer

At #ASCO25, Dr. Inimfon Jackson, with mentor Dr. Mariana Chavez Mac Gregor, presented data on chemotherapy declination in early-stage HR+ breast cancer. Among patients with high Oncotype DX scores, 11% declined chemotherapy despite physician recommendation. This was associated

Dr. Marija Sullivan shared real-world insights on Oncotype DX testing and chemotherapy use in early-stage HR+ breast cancer at #ASCO25. The data show variation in testing and treatment patterns by recurrence score, age, insurance type and other clinical factors. #EndCancer

Cindy Y. Jiang is doing some impressive work on MTAP loss in bladder cancer. Come check it out. MD Anderson Cancer Center #ASCO25 #endcancer

Huge congratulations to my friend and MD Anderson Cancer Center co-fellow Marija Sullivan, MD on her impactful work looking at the real-world patterns of Oncotype testing & chemo use in early-stage HR+ breast cancer #ASCO25

Very exciting!!! We need new drugs especially in mTNBC and especially post topo-1 ADCs as they move further up in our treatment paradigm

So thankful to Conquer Cancer, the ASCO Foundation for the 2025 ASCO YIA! I am especially grateful to my amazing mentors and to MD Anderson Cancer Center for their unwavering support and guidance. Congrats to my fellow awardees. Proud to be a part of this inspiring group! #makingcancerhistory

Congratulations to the MD Anderson Cancer Center trainees who received 2025 Conquer Cancer, the ASCO Foundation Young Investigator and Merit Awards for their contributions to cancer research! Extremely grateful for your hard work and commitment to our mission to #EndCancer. So well-deserved!